Geftiwel 250mg Tablet contains Gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC). Gefitinib works by inhibiting the intracellular phosphorylation of tyrosine kinase associated with the EGFR, thereby blocking downstream signaling pathways involved in tumor cell proliferation, survival, and metastasis. This targeted therapy is indicated for patients with locally advanced or metastatic NSCLC harboring specific EGFR mutations. Geftiwel 250mg is administered orally, typically once daily, and should be taken consistently at the same time each day to maintain steady plasma levels. Common adverse effects include diarrhea, rash, acneiform dermatitis, and nausea, which are generally manageable with supportive care. Serious adverse reactions may include interstitial lung disease, hepatotoxicity, and ocular disorders, necessitating close monitoring during treatment. Dose adjustments or discontinuation may be required based on toxicity severity. Prior to initiation, EGFR mutation testing is recommended to identify suitable candidates. Geftiwel should be used under strict medical supervision, with periodic assessment of liver function, pulmonary status, and dermatologic evaluation. It is contraindicated in patients with hypersensitivity to Gefitinib or any of its excipients. This medication offers a targeted therapeutic option, improving progression-free survival in selected NSCLC patients.